Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04077099 · ClinicalTrials.gov registry record · Phase 1

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

A Phase 1 study of NSCLC, sponsored by Regeneron Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
231
Enrollment target
20
Study locations

NCT04077099 is a Phase 1 study of NSCLC that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 231 participants, roughly in line with the 221-participant average among 71 other NSCLC trials with a reported enrollment target. The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04077099, a Phase 1 study of NSCLC, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
231 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body

Conditions Studied

NSCLC

Interventions

  • DRUG REGN5093

Study Locations (20)

New York

  • NYU Cancer Institute - New York
  • Icahn School of Medicine at Mount Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

Massachusetts

  • DNU_Massachusetts General Hospital_DNU - Boston
  • Dana Farber Harvard Cancer Center Consortium - Boston

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia
  • University of Pittsburgh UPMC - Clinical Research Services - Pittsburgh

Texas

  • Harold C. Simmons Comprehensive Cancer Center - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • University of California Irvine Medical Center - Bldg 56, RT81, Rm 241 - Orange

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Florida

  • Moffitt Cancer Center - McKinley Drive - Tampa

Trial Details

FieldValue
Enrollment Target 231 participants
Start Date 2020-01-07
Est. Completion 2032-04-22
Phase Phase 1

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04077099

The ClinicalTrials.gov registry entry for NCT04077099 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 221-participant average among 71 other NSCLC trials with a reported enrollment target. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 1 intervention - of which REGN5093 is the first listed.

NCT04077099 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Massachusetts, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04077099 about?

NCT04077099 is a clinical study titled "A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer". This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of...

What is the current status of trial NCT04077099?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 231 participants. The study started on 2020-01-07. Estimated completion is 2032-04-22.

What conditions does trial NCT04077099 study?

This clinical trial studies the following conditions: NSCLC.

What interventions are being tested in trial NCT04077099?

The interventions under investigation include: REGN5093 (DRUG).

Who is sponsoring clinical trial NCT04077099?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04077099 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

NSCLC

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.